Format

Send to

Choose Destination
See comment in PubMed Commons below
Nat Rev Clin Oncol. 2011 Aug 23;8(11):661-8. doi: 10.1038/nrclinonc.2011.126.

Personalized medicine in lung cancer: what we need to know.

Author information

  • 1Department of Clinical Oncology, The Chinese University of Hong Kong, State Key Laboratory of South China, Sha Tin, Hong Kong, China. tony@clo.cuhk.edu.hk

Abstract

Lung cancer is a complex and often fatal disease. The recent discovery of activating mutations in EGFR and fusion genes involving ALK has set the stage for personalized medicine for lung cancer. Patients selected using biomarkers have benefited from the development of EGFR tyrosine kinase inhibitors and ALK inhibitors with considerable improvement in tumor control and survival. Four key areas of knowledge that are essential to the development of targeted therapy are discussed in this Review: knowing the target, knowing the biomarker, knowing the end point and knowing the mechanisms of resistance.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group
    Loading ...
    Write to the Help Desk